CTOs on the Move

Locus Biosciences

www.locus-bio.com

 
Locus Biosciences` novel approach to precision antimicrobials works by taking advantage of an immune system present in many bacteria called the CRISPR-Cas system. The CRISPR-Cas system protects bacteria from invaders such as viruses by creating a small strand of RNA called a CRISPR RNA, which matches a DNA sequence specific to a given invader. If the CRISPR RNA is matched to a complementary DNA sequence, the Cas proteins will cleave the invading DNA.
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million
  • www.locus-bio.com
  • 7020 Kit Creek Road Suite 210
    Research Triangle Park, NC USA
  • Phone: 919.313.9648

Executives

Name Title Contact Details

Funding

Locus Biosciences raised $19M on 11/14/2017

Similar Companies

Pathwork Diagnostics

Pathwork Diagnostics is a Redwood City, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Phylagen

Phylagen is a venture-backed microbiome data analytics company that harnesses the vast, unseen world of microbes to improve business performance and make our lives better.

Precision Diagnostics

Precision Diagnostics, a leader in clinical laboratory testing and medication adherence monitoring, is transforming healthcare through the delivery of comprehensive, insightful clinical data that can help improve patient outcomes and manage costs. Spec...

CombiMatrix Corporation

CombiMatrix Corporation is a Irvine, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

ViaCyte

ViaCyte is a privately held regenerative medicine company developing novel cell replacement therapies as potential long-term diabetes treatments to achieve glucose control targets and reduce the risk of hypoglycemia and diabetes-related complications. ViaCyte`s product candidates are based on directed differentiation of pluripotent stem cells into PEC-01 pancreatic islet progenitor cells, which are then implanted in durable and retrievable cell delivery devices. ViaCyte demonstrated that when effectively engrafted, PEC-01 cells can mature into glucose-responsive insulin producing cells in patients with type 1 diabetes. To accelerate and expand its efforts, ViaCyte has established collaborative partnerships with leading companies including CRISPR Therapeutics and W.L. Gore & Associates.